

Table 3. Fasting blood glucose (mg/dL).

Time	Measure	Glibenclamide (N=60)	Insulin (N=60)	^P-value	Effect size Mean±SE 95% CI
Baseline	Mean±SD	139.9±12.5	138.9±11.9	0.650	1.0±2.2
	Range	113.0–160.0	111.0–159.0		-3.4–5.4
Week 30-32	Mean±SD	123.4±11.1	120.3±14.2	0.187	3.1±2.3
	Range	98.0–150.0	95.0–155.0		-1.5–7.7
Week 36-38	Mean±SD	119.5±15.0	115.8±12.1	0.143	3.7±2.5
	Range	91.0–151.0	89.0–140.0		-1.3–8.6
Change at week 30-32	Mean±SD	-16.5±8.3	-18.6±11.3	0.255	2.1±1.8
	Range	-34.0–2.0	-44.0–5.0		-1.5–5.6
Change at week 36-38	Mean±SD	-20.5±8.4	-23.1±6.7	0.058	2.7±1.4
	Range	-39.0--6.0	-40.0--7.0		-0.1–5.4

^Independent t-test. Effect size: Value of Glibenclamide relative to insulin. SE: Standard error. CI: Confidence interval.

Change=follow up - baseline, negative values indicate reduction.